A second patent can be found, but it was terminated in 2003 because it was not paid. And this patent seems to have nothing to do with the two drugs you mentioned. There are many fake drugs now, so be careful not to be fooled.
Application number: 98 1 1060 1 application date: 1998/0 1/05.
Date of publication:1998/0819 Date of publication: 2000/07/05.
ReleaseNo.: 1 190656 AnnouncementNo.: 1054 132.
Date of authorization: date of authorization announcement: July 5, 2000
Patent category: country, province and city of invention code: 3 1
Organization code: 3 1203 [cross-reference table] Manager: Luo.
Method for separating thymidine from mixture
International classification number: C07H1/06; C07H 19/06
Category number: 18G
Inventor: Qiu; Shao rensen; Shao Xuefeng
Applicant: East China University of Science and Technology; Shanghai Libo biochemical factory
Applicant's address: No.0/30, Meilong Road, Shanghai.
Postal code: 200237
abstract:
The invention belongs to the technical field of biochemical engineering, and relates to a method for separating thymidine from a mixture. The method comprises the following steps: a thymidine solution containing impurities obtained by a chemical synthesis method sequentially flows through a macroporous phenolic weak acid cation exchange resin and a macroporous weak base acrylic anion exchange resin, and a proper amount of borate is added into the solution to improve the purity of thymidine products; For thymidine solution obtained by enzymatic hydrolysis, strong acid cation exchange resin can be added to better remove impurities in the solution. The method has the advantages of simple process, high product yield and purity of more than 99%, and can meet the needs of industrial production.
Main propositions:
A method for separating thymidine from a mixture mainly comprises the processes of impurity removal, concentration (2), crystallization (3) and filtration (4), and is characterized in that the impurity removal is that an aqueous solution of thymidine containing impurities sequentially flows through two series-connected ion exchange resin columns, wherein the ion exchange resin columns are a macroporous phenolic resin column (1) and a macroporous weak base acrylic resin column.
Priority projects:
PCT clause
Legal Status: [Disclaimer] 2003-2-26; Termination due to expenses